DETAILED NOTES ON BOSENTAN

6 The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV during the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) like bosentan, sitaxentan and ambrisentan are oral therapies licensed to be used in PAH. As no oral agent has proven superiority there stays debate regarding which needs to be